JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Found 321 products of "JAK/STAT signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Neocucurbitacin A
CAS:<p>Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].</p>Formula:C31H42O8Purity:98%Color and Shape:SolidMolecular weight:542.66SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formula:C36H36N10O5Color and Shape:SolidMolecular weight:688.74JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formula:C30H32N8O5SColor and Shape:SolidMolecular weight:616.69S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formula:C17H18N6Purity:98%Color and Shape:SolidMolecular weight:306.37PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formula:C55H69N13O7SPurity:98%Color and Shape:SolidMolecular weight:1056.28TP-5801 TFA
<p>TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 value of 1.40 nM, demonstrating anti-tumor activity [1].</p>Formula:C26H32BrF3N8O3Purity:98%Color and Shape:SolidMolecular weight:641.48Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formula:C17H18N6Color and Shape:SolidMolecular weight:314.41HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formula:C60H69N17O11SColor and Shape:SolidMolecular weight:1236.36MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54KT-333 diammonium
CAS:<p>KT-333 diammonium functions as a molecular glue that targets and degrades the STAT3 protein. It selectively mediates the degradation of STAT3 via the ubiquitin-proteasome pathway by attaching to STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). This compound exhibits strong specificity in degrading STAT3 and demonstrates significant antitumor activity. KT-333 diammonium is applicable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).</p>Formula:C60H80ClN12O14PSColor and Shape:SolidMolecular weight:1291.84KT-333 ammonium
CAS:<p>KT-333 ammonium (Compound A) acts as a molecular glue that targets and promotes the degradation of the STAT3 protein through the ubiquitin-proteasome system. This compound achieves selective degradation by binding simultaneously to the STAT3 protein and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). It exhibits strong selectivity and efficacy in degrading STAT3, possessing notable antitumor properties. KT-333 ammonium is particularly useful for research on hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) [1].</p>Formula:C60H77ClN11O14PSColor and Shape:SolidMolecular weight:1274.81TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485Fulipiftide
CAS:<p>Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). It stimulates the amplification of nuclear stem cell factor+TSPC by activating the ERK2 and STAT3 signaling pathways. Fulipiftide also exhibits anti-inflammatory properties and is applicable in research on acute tendon injuries.</p>Formula:C144H227N41O47Color and Shape:SolidMolecular weight:3284.59DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formula:C25H38N4O3Color and Shape:SolidMolecular weight:442.59SD-2301
CAS:<p>SD-2301 is a PROTAC degrader of STAT3.</p>Formula:C64H80N13O15PS2Color and Shape:SolidMolecular weight:1366.50WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formula:C29H31F3N4O4Color and Shape:SolidMolecular weight:556.576Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formula:C23H25F5N7O5PPurity:99.57%Color and Shape:SolidMolecular weight:605.45STAT3-IN-41
<p>STAT3-IN-41 (Compound 16) is a prodrug of compound 1. It gradually releases compound 1, which inhibits the STAT3 signaling pathway. STAT3-IN-41 exhibits antitumor activity against lung cancer, hepatocellular carcinoma, and pancreatic cancer.</p>Formula:C22H30F3NO7Color and Shape:SolidMolecular weight:477.471Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Color and Shape:Odour SolidPROTAC STAT3 degrader-2
CAS:<p>PROTAC STAT3 degrader-2 selectively breaks down STAT3 (DC50: 3.54μM, Molm-16) with cancer research potential.</p>Formula:C59H60F2N9O13PColor and Shape:SolidMolecular weight:1172.13Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidAtinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formula:C16H17FN6O3Purity:99.36%Color and Shape:SolidMolecular weight:360.35CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formula:C22H19F2N5O2Purity:99.38%Color and Shape:SolidMolecular weight:423.42SD-436
CAS:<p>SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.</p>Formula:C58H62F4N9O14PSPurity:99.34%Color and Shape:SolidMolecular weight:1248.2DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6Pim-1/2 kinase inhibitor 1
CAS:<p>Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.</p>Formula:C11H9NO3SPurity:99.78%Color and Shape:SolidMolecular weight:235.26Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formula:C32H33F4N9O5Color and Shape:SolidMolecular weight:699.66Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formula:C17H17N7O2SPurity:99.88%Color and Shape:SolidMolecular weight:383.43AK-1690
CAS:<p>AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells and depletes STAT6 proteins in mouse tissues.</p>Formula:C51H56F2N5O11PSPurity:99.95%Color and Shape:SolidMolecular weight:1016.055,15-DPP
CAS:<p>5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist with IC 50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively [1].</p>Formula:C32H22N4Color and Shape:SolidMolecular weight:462.54Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formula:C28H32O6Purity:97% - 97.90%Color and Shape:SolidMolecular weight:464.55Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Formula:C21H23N5O3SPurity:98.03% - ≥95%Color and Shape:SolidMolecular weight:425.5RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formula:C29H35N7O4Purity:98% - 99.91%Color and Shape:SolidMolecular weight:545.63JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formula:C19H18N4O3Purity:99.94% - 99.94%Color and Shape:SolidMolecular weight:350.37Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formula:C15H19N5OPurity:98.82% - 99.92%Color and Shape:SolidMolecular weight:285.34SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formula:C18H22N8O2SPurity:99.11%Color and Shape:SolidMolecular weight:414.48AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Formula:C14H5F6N5OPurity:98% - 98.85%Color and Shape:SolidMolecular weight:373.21SMI-16a
CAS:<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Formula:C13H13NO3SPurity:99.99%Color and Shape:SolidMolecular weight:263.31SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formula:C21H18ClFN4O4Purity:98.99% - 99.77%Color and Shape:SolidMolecular weight:444.84XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formula:C25H28N6O2Purity:99.19%Color and Shape:SolidMolecular weight:444.53Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formula:C23H24Cl2N6O2Color and Shape:SolidMolecular weight:487.38Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Formula:C15H18O2Purity:97.55% - 99.92%Color and Shape:SolidMolecular weight:230.3TCS-PIM-1-4a
CAS:<p>SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).</p>Formula:C11H6F3NO2SPurity:99.89%Color and Shape:SolidMolecular weight:273.23Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formula:C18H22N4O2Purity:98.67% - 99.4%Color and Shape:SolidMolecular weight:326.39Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Formula:C24H29ClN8O2Color and Shape:SolidMolecular weight:497Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36
